TuHURA Biosciences (HURA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Jun, 2026Executive summary
The annual meeting will be held virtually on August 18, 2026, with six key proposals up for shareholder vote, including director elections, approval of share issuance, executive compensation, vote frequency, auditor ratification, and adjournment authority.
Shareholders of record as of June 26, 2026, are entitled to vote, with a quorum set at one-third of outstanding shares.
The board unanimously recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposal 1: Elect six directors to serve until the 2027 annual meeting.
Proposal 2: Approve issuance of 1,878,287 shares to Parkview Holdings One LLC under a fee agreement, as required by Nasdaq rules.
Proposal 3: Advisory vote on executive compensation (say-on-pay).
Proposal 4: Advisory vote on frequency of future say-on-pay votes, with board recommending every three years.
Proposal 5: Ratify Cherry Bekaert LLP as independent auditor for 2026.
Proposal 6: Authorize adjournment of the meeting if necessary to solicit additional proxies.
Board of directors and corporate governance
Board consists of six members, with a majority qualifying as independent under Nasdaq rules.
Committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and independent membership.
Board leadership separates the roles of Chairman and President/CEO.
Code of Ethics and Insider Trading Policy are in place for directors, officers, and employees.
Latest events from TuHURA Biosciences
- Clinical-stage immuno-oncology firm expands pipeline via merger, but faces ongoing financial and execution risks.HURA
Registration filing22 Jun 2026 - Diversified immuno-oncology pipeline advances amid ongoing losses and high funding needs.HURA
Registration filing22 Jun 2026 - Up to $250M in securities registered, including $50M ATM, to fund oncology pipeline and operations.HURA
Registration filing22 Jun 2026 - Merger completed, cash burn persists, and urgent funding needs threaten going concern.HURA
Q3 20249 Jun 2026 - Phase 3 IFx-2.0 trial and Kineta acquisition drive growth, backed by $36M in new funding.HURA
Q4 20249 Jun 2026 - Net loss widened to $6.7M in Q1 2025; pipeline and merger progress drive outlook.HURA
Q1 20259 Jun 2026 - Net loss rose to $7.1M in Q3 2025 as R&D spending increased and liquidity concerns persist.HURA
Q3 20259 Jun 2026 - Q2 2025 net loss rose to $9.5M as costs surged post-Kineta merger; $15.5M in new funding raised.HURA
Q2 20259 Jun 2026 - $50M credit facility and rising R&D spending support clinical milestones through 2028.HURA
Q1 20269 Jun 2026